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India had forced upon itself a complete lockdown 
for almost 2 months since March 2020 to fight 
against an unseen enemy—Severe acute 
respiratory syndrome Corona virus 2 (SARS-
CoV-2). Now with restrictions being lifted almost 
completely across the entire nation, the number 
of new coronavirus cases has seen a steep rise 
along with an increase in mortality rate. 
Research being done across the nations has 
shown that corona virus disease 2019 (COVID-
19) infection causes serious consequences in 
elderly, those with metabolic and chronic 
disorders like hypertension, diabetes mellitus, 
renal diseases, hyperlipidemia, etc. 
Since the renin-angiotensin system (RAS) is 
involved in these patients, drugs which can 
modulate this system are now being considered 
as the drug of choice in COVID-19 patients and 
also used for prevention of any vascular 
complications in such cases [1]. 
The dynamic control of vascular function is 
known to be regulated by different regulatory 
proteins and peptides included in renin-
angiotensin system. The RAS is not only 
involved in blood pressure homeostatic 
mechanisms, it also regulates sodium levels and 
blood volume in the body. While it is known that 
angiotensin-I is converted to angiotensin-II by 
angiotensin converting enzyme (ACE), the role of 
angiotensin converting enzyme 2 (ACE2) which 
metabolizes Angiotensin-I to Ang 1-9 and 
Angiotensin-II to Ang 1-7 has been recently 
elucidated [2]. 
ACE2 enzyme belongs to a family of dipeptidyl 
carboxypeptidases. It is expressed by most of 
the tissues in the body with greater expression in 
renal, cardiac and pulmonary tissues; and in 
vascular endothelial cells [3]. 
SARS-CoV-2 is an example of a single-stranded 
RNA virus which has the capability to enter the 
host cell due to the presence of S-protein 
(envelope spike glycoprotein). This same protein 
is also responsible for transmitting the disease 
from one host to another. It causes reduction in 
expression of ACE2 thereby increasing chances 
of lung injury [4,5], increased formation of 
atherosclerotic plaques [6], increased incidence 
of cardiac fibrosis [2], diabetic and hypertensive 
nephropathy [6]. 
Due to the widespread location of ACE2 in 
different tissues like lungs, kidney, blood vessels, 
intestine, the symptomatology of COVID-19 
infection also differs; varying from pneumonia, 
bronchitis to gastrointestinal illness. 
Another interesting observation regarding 
COVID-19 infection is the relatively protective 
effect of circulating ACE2 levels in females 
compared to males. Higher expression of tissue 
ACE2 in males; and negative correlation of ACE2 
activity with body mass index (BMI), estrogen 
levels and pulse pressure in females is one of 
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the reasons why incidence of COVID-19 infection 
in females has been less. There is also enough 
evidence to show that in children the incidence of 
COVID-19 infection is less compared to adults; 
this too has been subjected to higher levels of 
circulating ACE2 in children [7]. 
Therapeutic strategies adopted against SARS-
CoV-2 targets ACE2 receptor since it has been 
proved to be the entry point for the coronavirus to 
gain access to body tissues. Neutralizing 
antibodies present in convalescent sera against 
the SARS protein also offers protection against 
COVID-19 infection [8]. However a statement 
issued in public interest by American Heart 
Association (AHA) stating that there is no strong 
evidence to prove harm or benefit of ACE-
inhibitors or angiotensin-I receptor blockers has 
provide some relief to medical practitioners 
across nations [9].  
As far as clinical trials on corona vaccine are 
concerned, COVID-19 vaccine, developed by US 
drug biotech firm Moderna, triggered an immune 
response in people, and has also prevented the 
development of lung infections in mice. Similar 
trials in monkeys have also showed promising 
results. Yet it would be another 12-18 months 
before the corona vaccines be actually available 
and be useful to patients infected with this deadly 
virus [10]. India became fifth country to isolate 
the SARS-CoV-2 when National Institute of 
Virology (NIV), Pune, a premier constituent 
institute of Indian Council on Medical Research 
(ICMR), New Delhi retrieved the virus from the 
affected patient’s sample. This has put India on 
path of developing vaccine against this highly 
infectious virus. 
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